Establishment of novel immunotherapy against malignant mesothelioma

恶性胸膜间皮瘤（MPM）是一种侵袭性恶性肿瘤。因此，迫切需要新的治疗策略来改善MPM的预后。在本研究中，我研究了抗HM 1.24抗体是否能诱导抗MPM的抗肿瘤作用。免疫组化显示HM 1.24在MPM细胞株和恶性间皮瘤组织中均有表达。此外，抗HM 1.24抗体可诱导针对HM 1.24阳性MPM细胞的ADCC和CDC。这些结果强烈表明，治疗性抗体的靶向治疗可能是有用的，作为一种新的免疫治疗MPM。

Malignant pleural mesothelioma (MPM) is an aggressive malignancy. Therefore, novel therapeutic strategies for MPM are urgently necessary for improving the prognosis. In this study, I investigated whether anti-HM1.24 antibody can induce antitumor effects against MPM. Immunostaining showed the expression of HM1.24 of MPM cell lines and malignant mesothelioma tissues. Furthermore, anti-HM1.24 antibody could induce potent ADCC and CDC against HM1.24-positive MPM cells. These results strongly suggest that targeting therapy with therapeutic antibodies might be useful as a novel immunotherapy against MPM.